Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 13/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10194995 | 0.88 | P2RY14 (0.49) | P2RY14ADRA2AADRA2CADRA2BOPRD1 | |
| SCHEMBL10195056 | 0.87 | P2RY14 (0.58) | P2RY14ADRA2AADRA2CADRA2BOPRD1 | |
| SCHEMBL10195395 | 0.86 | P2RY14 (0.46) | P2RY14ADRA2AADRA2CADRA2BOPRD1 | |
| Hydrochloric Acid SCHEMBL9959222 | 0.85 | P2RY14 (0.46) | P2RY14ADRA2AADRA2CADRA2BOPRD1 | |
| SCHEMBL10194743 | 0.85 | P2RY14 (0.39) | P2RY14ADRA2AADRA2CADRA2BOPRD1 | |
| SCHEMBL10194951 | 0.85 | HTR2A (0.37) | P2RY14ADRA2AADRA2CADRA2BOPRD1 | |
| SCHEMBL10196959 | 0.85 | HTR2A (0.39) | P2RY14ADRA2AADRA2CADRA2BOPRD1 | |
| SCHEMBL17850463 | 0.85 | HTR2A (0.39) | P2RY14ADRA2AADRA2CADRA2BOPRD1 | |
| SCHEMBL10194860 | 0.83 | FGFR1 (0.39) | P2RY14ADRA2AADRA2CADRA2BOPRD1 | |
| SCHEMBL10194878 | 0.83 | P2RY14 (0.44) | P2RY14ADRA2AADRA2CADRA2BOPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655357-B1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | MERCK SERONO SA (CH) | 2016-06-22 | — | — | EP | disclosed |
| US-9073892-B2 | Indazolyl triazol derivatives | MERCK SERONO S.A. (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9073892-B2 | Indazolyl triazol derivatives | MERCK SERONO S.A. (CH) | 2015-07-07 | — | — | US | disclosed |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) | 2013-10-17 | — | — | US | disclosed |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) | 2013-10-17 | — | — | US | disclosed |
| WO-2012084704-A1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | MERCK SERONO S.A. (CH) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | NFATC1, IL5, CD4 | P2RY14 2361/4885ADRA2A 2876/4885ADRA2C 2520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.